Merck has reported positive topline findings from the Phase 3 KEYNOTE-C93 trial, demonstrating that pembrolizumab (KEYTRUDA®) significantly extended progression-free survival (PFS) compared with standard platinum-based chemotherapy in patients with mismatch…
Acknowledgment: This story is sponsored by GSK and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted, and valuable…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Karyopharm is currently developing selinexor, an investigational treatment for recurrent or advanced endometrial cancer. They had planned to submit a supplemental New Drug Application (sNDA) to the FDA, but now…
European patients with recurrent or advanced endometrial carcinoma have a new treatment option, as the European Commission (EC) has approved KEYTRUDA plus LENVIMA. Approval is specifically for adult patients whose…
Endometrial cancer is the most common form of cancer that develops in the uterus, and there is currently a need for more treatment options, especially when it comes to the…
The FDA has recently approved KEYTRUDA (pembrolizumab) in combination with LENVIMA (lenvatinib) for the treatment of advanced endometrial carcinoma that is not mismatch repair deficiency or microsatellite instability-high. This approval…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
The healthcare system is designed to provide safe, effective, and beneficial care for all. Unfortunately, the current system represents a wealth of socioeconomic and racial disparities. Past studies have shown…
From June 4-8, 2021, the American Society of Clinical Oncology (ASCO) held its Annual Meeting to discuss trends and research within the oncology field. According to Cancer Therapy Advisor,…
According to MarketScreener, patients with endometrial cancer in Europe now have a new treatment option. Recently, the European Commission (EC) granted conditional marketing authorization to GlaxoSmithKline for their therapy JEMPERLI…
Typically, the pathway to diagnosis for endometrial cancer can be long, uncomfortable, and invasive: transvaginal ultrasounds, biopsies. However, this may be about to change. In a recent press release, Arquer…
There are many forms of birth control available: oral contraceptives (birth control pills), intrauterine devices (IUDs), the implant or patch, condoms. But according to Cancer Therapy Advisor, a new study…
According to a publication from the University of Edinburgh, a new study found a set of 37 genes that were highly expressed in breast cancer tumour-associated macrophages (or TAMs -…
According to a story from Genetic Obesity News, the unusual case of a female Bardet-Biedl syndrome patient who also had endometrial cancer is causing researchers to wonder if the two…
According to a story from whtc.com, a recent study from the UK is calling into question the widely held belief that fertility treatments could increase the risk of ovarian cancer,…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
